Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURFAXIN aerosol via nCPAP for RDS prevention in premature infants
NCT00807235Phase 2Terminated
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Jan 2005
- Primary completion
- Aug 2005
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lucinactant in respiratory distress syndrome (RDS), sponsored by Windtree Therapeutics, Inc.. Started Jan 2005; status: terminated.
02
Drugs
lucinactant
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT00807235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00807235.